Earnings ·
Reports Q3 revenue of $341.3M and raises full-year guidance midpoint
PGNYProgyny, Inc.
Progyny reported third-quarter revenue of $341.3 million, an 8.9% increase from the prior year period, driven by growth in clients and covered lives. Net income rose to $26.3 million, or $0.32 per diluted share, compared to $13.9 million in the same quarter last year. Adjusted EBITDA reached $58.4 million with a 17.1% margin. The company added 1.3 million new covered lives and achieved near-100% retention for 2027. Management raised the midpoint of its full-year revenue guidance to reflect strong momentum and expectations for member engagement in the remainder of the year. Progyny operates as a global leader in women's health and family building solutions, providing fertility benefits, pharmacy support, and care advocacy services.